Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod

Primary central nervous system lymphoma (PCNSL) is an uncommon lymphoproliferative disease associated with immunosuppression. Here, we report the case of a patient with multiple sclerosis, under treatment with fingolimod (FTY720, Gilenya) for 4 years, who developed this condition. Although the causa...

Full description

Saved in:
Bibliographic Details
Published in:Neurological sciences 2023, Vol.44 (1), p.361-363
Main Authors: Morillos, Matheus Bernardon, de Aguiar, Paulo Henrique Pires, Franceschini, Paulo Roberto, Duarte, Juliana Ávila, Piccini, Cristian Daniel, Finkelsztejn, Alessandro
Format: Article
Language:English
Subjects:
Central nervous system
Central Nervous System - pathology
Epidemiology
Fingolimod Hydrochloride - adverse effects
FTY720
Humans
Immunoproliferative diseases
Immunosuppression
Immunosuppressive agents
Immunosuppressive Agents - adverse effects
Letter to the Editor
Lymphocytes
Lymphoma
Lymphoma - chemically induced
Lymphoma - complications
Lymphoma - drug therapy
Medicine
Medicine & Public Health
Multiple sclerosis
Multiple Sclerosis - complications
Multiple Sclerosis - drug therapy
Multiple Sclerosis - pathology
Neurology
Neuroradiology
Neurosurgery
Psychiatry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary central nervous system lymphoma (PCNSL) is an uncommon lymphoproliferative disease associated with immunosuppression. Here, we report the case of a patient with multiple sclerosis, under treatment with fingolimod (FTY720, Gilenya) for 4 years, who developed this condition. Although the causal relationship cannot be established, there are cases in the literature that describe the appearance of lymphoma after the use of this medication. Considering the high mortality of PCNSL, epidemiological studies are necessary to establish a relationship between its arising and the use of immunosuppressants.
ISSN:1590-1874
1590-3478
DOI:10.1007/s10072-022-06367-3